Aerosol Treatment of Children |

Aerosol Treatment of Children

Bioequivalence of novel aerosol and existing reference product needs documentation.

The airway in the younger child differs from the airway in the adult and the amount of the dose of an inhaled drug reaching the lower airway in an infant and in a young child will differ from the amount which would reach the lower airway in an adult. Changes in development, maturation and growth of the lung from birth, through infancy and early childhood can affect absorption and clearance of drug from the lung with possible changes in respect of optimal dosing in this young age group and changes in both efficacy and systemic safety. The child also displays different breathing patterns and has differing tidal volumes, airway geometry, etc. compared with adults [1].

This website present methods for such evidence based documentation of bioavailability of aerosol treatment of children.


  1. Drug Delivery to the Lung. Vol. 162. Bisgaard H, O'Callaghan C, Smaldone GC, eds. New York: Marcel Dekker; 2002.
Professor Hans Bisgaard • Copenhagen • Denmark •